Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice

Annals of Neurology

Volumn 77, Issue 4, 2015, Pages 637-654

  Zhou, Qiong ^a   Wang, Man ^a   Du, Ying ^a   Zhang, Wei ^a   Bai, Miao ^a   Zhang, Zhuo ^a   Li, Zhuyi ^a   Miao, Jianting ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA SECRETASE; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; INTERLEUKIN 6; STRESS ACTIVATED PROTEIN KINASE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; PRESENILIN 1;

ADULT; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN CORTEX; BRAIN TISSUE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ESCAPE BEHAVIOR; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LATENT PERIOD; LONG TERM CARE; MICROGLIA; MIDDLE AGED; MOUSE; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SPATIAL LEARNING; SPATIAL MEMORY; SYNAPSE; SYSTEMIC THERAPY; THERAPY EFFECT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; METABOLISM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTHRACENES; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, TRANSGENIC; PHENOTYPE; PRESENILIN-1;

EID: 84925650240     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24361     Document Type: Article

References (59)

1. Querfurth HW, LaFerla FM,. Alzheimer's disease. N Engl J Med 2010; 362: 329-344.
2. Tayeb HO, Yang HD, Price BH, et al. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012; 134: 8-25.
3. Mehan S, Meena H, Sharma D, et al. JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities. J Mol Neurosci 2011; 43: 376-390.
4. Shoji M, Iwakami N, Takeuchi S, et al. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res 2000; 85: 221-233.
5. Zhu X, Raina AK, Rottkamp CA, et al. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem 2001; 76: 435-441.
6. Lagalwar S, Guillozet-Bongaarts AL, Berry RW, et al. Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in Alzheimer disease. J Neuropathol Exp Neurol 2006; 65: 455-464.
7. Thakur A, Wang X, Siedlak SL, et al. c-Jun phosphorylation in Alzheimer disease. J Neurosci Res 2007; 85: 1668-1673.
8. Savage MJ, Lin YG, Ciallella JR, et al. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 2002; 22: 3376-3385.
9. Puig B, Gõmez-Isla T, Ribé E, et al. Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 2004; 30: 491-502.
10. Braithwaite SP, Schmid RS, He DN, et al. Inhibition of c-Jun kinase provides neuroprotection in a model of Alzheimer's disease. Neurobiol Dis 2010; 39: 311-317.
11. Sclip A, Antoniou X, Colombo A, et al. c-Jun N-terminal kinase regulates soluble Aβ oligomers and cognitive impairment in AD mouse model. J Biol Chem 2011; 286: 43871-43880.
12. Colombo A, Repici M, Pesaresi M, et al. The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability. Cell Death Differ 2007; 14: 1845-1848.
13. Colombo A, Bastone A, Ploia C, et al. JNK regulates APP cleavage and degradation in a model of Alzheimer's disease. Neurobiol Dis 2009; 33: 518-525.
14. Yoon SO, Park DJ, Ryu JC, et al. JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron 2012; 75: 824-837.
15. Morishima Y, Gotoh Y, Zieg J, et al. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 2001; 21: 7551-7560.
16. Wang Q, Walsh DM, Rowan MJ, et al. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004; 24: 3370-3378.
17. Yenki P, Khodagholi F, Shaerzadeh F,. Inhibition of phosphorylation of JNK suppresses Aβ-induced ER stress and upregulates prosurvival mitochondrial proteins in rat hippocampus. J Mol Neurosci 2013; 49: 262-269.
18. Ghasemi R, Zarifkar A, Rastegar K, et al. Repeated intra-hippocampal injection of beta-amyloid 25-35 induces a reproducible impairment of learning and memory: considering caspase-3 and MAPKs activity. Eur J Pharmacol 2014; 726C: 33-40.
19. Yoshida H, Hastie CJ, McLauchlan H, et al. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). J Neurochem 2004; 90: 352-358.
20. Tatebayashi Y, Planel E, Chui DH, et al. c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J 2006; 20: 762-764.
21. Ploia C, Antoniou X, Sclip A, et al. JNK plays a key role in tau hyperphosphorylation in Alzheimer's disease models. J Alzheimers Dis 2011; 26: 315-329.
22. Vogel J, Anand VS, Ludwig B, et al. The JNK pathway amplifies and drives subcellular changes in tau phosphorylation. Neuropharmacology 2009; 57: 539-550.
23. Vukic V, Callaghan D, Walker D, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009; 34: 95-106.
24. Bamji-Mirza M, Callaghan D, Najem D, et al. Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-β-induced signaling dysregulation and inflammatory response. J Alzheimers Dis 2014; 40: 105-122.
25. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001; 98: 13681-13686.
26. Okuno S, Saito A, Hayashi T, et al. The c-Jun N-terminal protein kinase signaling pathway mediates Bax activation and subsequent neuronal apoptosis through interaction with Bim after transient focal cerebral ischemia. J Neurosci 2004; 24: 7879-7887.
27. Gao Y, Signore AP, Yin W, et al. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J Cereb Blood Flow Metab 2005; 25: 694-712.
28. Chen D, Wei XT, Guan JH, et al. Inhibition of c-Jun N-terminal kinase prevents blood-brain barrier disruption and normalizes the expression of tight junction proteins clautin-5 and ZO-1 in a rat model of subarachnoid hemorrhage. Acta Neurochir (Wien) 2012; 154: 1469-1476.
29. Wang W, Shi L, Xie Y, et al. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci Res 2004; 48: 195-202.
30. Yatsushige H, Ostrowski RP, Tsubokawa T, et al. Role of c-Jun N-terminal kinase in early brain injury after subarachnoid hemorrhage. J Neurosci Res 2007; 85: 1436-1448.
31. Hong YK, Lee S, Park SH, et al. Inhibition of JNK/dFOXO pathway and caspases rescues neurological impairments in Drosophila Alzheimer's disease model. Biochem Biophys Res Commun 2012; 419: 49-53.
32. Zhang W, Bai M, Xi Y, et al. Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice. Neurobiol Aging 2012; 33: 2661-2677.
33. Ishrat T, Hoda MN, Khan MB, et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009; 19: 636-647.
34. Qu J, Zhou Q, Du Y, et al. Rutin protects against cognitive deficits and brain damage in rats with chronic cerebral hypoperfusion. Br J Pharmacol 2014; 171: 3702-3715.
35. Li JG, Chu J, Barrero C, et al. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol 2014; 75: 851-863.
36. Chu J, Praticò D,. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation 2012; 9: 127.
37. Guglielmotto M, Monteleone D, Giliberto L, et al. Amyloid-β42 activates the expression of BACE1 through the JNK pathway. J Alzheimers Dis 2011; 27: 871-883.
38. Tamagno E, Parola M, Bardini P, et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 2005; 92: 628-636.
39. Rahman M, Zhang Z, Mody AA, et al. Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and Notch signaling in mouse brain without induction of apoptosis. Brain Res 2012; 1448: 117-128.
40. Shen C, Chen Y, Liu H, et al. Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem 2008; 283: 17721-17730.
41. Lee MS, Kao SC, Lemere CA, et al. APP processing is regulated by cytoplasmic phosphorylation. J Cell Biol 2003; 163: 83-95.
42. Gong CX, Grundke-Iqbal I, Iqbal K,. Targeting tau protein in Alzheimer's disease. Drugs Aging 2010; 27: 351-365.
43. De Felice FG, Wu D, Lambert MP, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008; 29: 1334-1347.
44. Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 2009; 29: 9078-9089.
45. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, et al. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 2014; 8: 112.
46. Hong HS, Hwang EM, Sim HJ, et al. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 2003; 307: 922-927.
47. Liao YF, Wang BJ, Cheng HT, et al. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 2004; 279: 49523-49532.
48. Kim SH, Smith CJ, Van Eldik LJ,. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 2004; 25: 431-439.
49. Waetzig V, Czeloth K, Hidding U, et al. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia 2005; 50: 235-246.
50. Marcello E, Epis R, Saraceno C, et al. Synaptic dysfunction in Alzheimer's disease. Adv Exp Med Biol 2012; 970: 573-601.
51. Janz R, Südhof TC, Hammer RE, et al. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 1999; 24: 687-700.
52. El-Husseini AE, Schnell E, Chetkovich DM, et al. PSD-95 involvement in maturation of excitatory synapses. Science 2000; 290: 1364-1368.
53. Sclip A, Tozzi A, Abaza A, et al. c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death Dis 2014; 5: e1019.
54. Costello DA, Herron CE,. The role of c-Jun N-terminal kinase in the A beta-mediated impairment of LTP and regulation of synaptic transmission in the hippocampus. Neuropharmacology 2004; 46: 655-662.
55. Ramin M, Azizi P, Motamedi F, et al. Inhibition of JNK phosphorylation reverses memory deficit induced by β-amyloid (1-42) associated with decrease of apoptotic factors. Behav Brain Res 2011; 217: 424-431.
56. Munoz L, Ammit AJ,. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010; 58: 561-568.
57. Shukla V, Skuntz S, Pant HC,. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res 2012; 43: 655-662.
58. Llorens-Martín M, Jurado J, Hernández F, et al. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 2014; 7: 46.
59. Gandy S, DeKosky ST,. Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med 2013; 64: 367-383.